Talert

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Talert

Property Description
Active ingredient Cetirizine Hydrochloride
Form Oral tablets, solution, and syrup
Pharmacological class Second-generation Antihistamine
General purpose Relief of symptoms associated with allergies
Origin Synthetic compound (Piperazine derivative)

Talert is a branded medicinal preparation classified as a second-generation antihistamine, containing the active substance Cetirizine Hydrochloride. It belongs to the pharmacological group of piperazine derivatives, functioning as a selective peripheral H1 receptor antagonist. As such, the medicine works by specifically targeting the receptors responsible for allergic reactions. As a second-generation compound, Talert is clinically recognized for providing systemic relief while having a reduced propensity for causing significant drowsiness compared to older agents.


Classification and Composition

Talert is a synthetic, single-active-ingredient product intended for systemic oral administration. Its active core, Cetirizine Hydrochloride, is used worldwide in similar formulations, confirming its established global use profile. The drug is available in multiple dosage forms, including solid oral tablets and liquid preparations such as an oral solution or syrup, the latter being particularly important for accurate administration in pediatric patients. Cetirizine is a potent and selective H1 antagonist that is rapidly absorbed, providing relief from histamine-mediated symptoms.


Role in Allergy Relief

The core role of Talert is to manage the physical manifestations caused by the release of histamine in the body during an allergic reaction. Cetirizine Hydrochloride achieves this by blocking the H1 receptor sites, preventing histamine from binding and initiating the symptom cascade. This targeted action provides an anti-allergic effect that helps to alleviate discomforts associated with common allergic conditions. Therefore, Talert's fundamental purpose is to contribute to the overall symptomatic management of various allergic conditions, such as seasonal allergies or chronic hives.

What side effects are possible with Talert?

Possible Side Effects and Safety Information

This section describes the officially documented adverse reactions and safety characteristics of Talert (Cetirizine Hydrochloride) based strictly on government regulatory documents.


Frequency-Classified Adverse Reactions

Adverse reactions are classified by regulatory authorities based on observed frequency, using standard categories such as Common (may affect up to 1 in 10 people) and Uncommon (may affect up to 1 in 100 people).

The Common reactions primarily involve the Nervous System (e.g., somnolence, headache, dizziness, fatigue) and Gastrointestinal System (e.g., dry mouth, nausea).

Uncommon reactions include agitation, rash, pruritus (itching), paresthesia, and malaise. Reactions classified as Rare or Very Rare include more significant events such as tachycardia, convulsions, or hypersensitivity reactions (including anaphylactic shock), affecting the Immune, Cardiac, and Hepatobiliary System-Organ Classes.


Population-Specific Safety and Restrictions

Regulatory documentation establishes specific limitations and cautions for certain patient populations. Talert is contraindicated in individuals with known hypersensitivity to the active substance, hydroxyzine, or any piperazine derivatives. It is also contraindicated in patients with severe renal impairment (end-stage renal disease).

Caution is recommended for older individuals with potentially compromised renal function and for patients with predisposing factors for urinary retention. Furthermore, there are documented reports of severe pruritus and/or urticaria occurring upon discontinuation of the medicine, even if these symptoms were absent before treatment began.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation details the potential manifestations and required emergency actions for Talert (Cetirizine Hydrochloride) overdosage.

Documented Overdose Manifestations

Symptoms reported following an overdose are primarily related to the Central Nervous System (CNS), often resulting in somnolence, drowsiness, fatigue, confusion, and headache. Less common effects that have been officially documented include tachycardia (fast heart rate), tremor, urinary retention, and diarrhea.

Severe outcomes documented in regulatory sources include the potential for convulsions and specific cardiac risks, such as Torsades de Pointes, which has been reported in a patient with chronic renal failure following an overdosage. In pediatric patients, overdosage may present with restlessness and irritability before drowsiness.

Regulator-Mandated Emergency Actions

Regulatory authorities explicitly mandate that individuals seek immediate medical attention or contact a Poison Control Center right away in case of overdose. Emergency services must be called if the affected individual has collapsed, had a seizure, has trouble breathing, or cannot be awakened.

Official Management Context

It is stated that there is no known specific antidote to the substance. Management of overdosage is defined as symptomatic and supportive treatment, with guidance that procedures like gastric lavage may be considered shortly after drug ingestion.

Therapeutic Uses of Talert

What Talert Treats: Main Uses and Benefits

Talert is generally used for managing certain distressing symptoms related to physical discomfort, contributing to symptomatic relief across key domains of allergic conditions in both adults and children. It is applied across domains where additional symptomatic support is needed to cope with episodes of heightened patient distress. The medication is utilized for its primary indications in conditions presenting with acute episodes.

The medication is commonly used to help with managing conditions presenting with systemic or localized discomfort, namely allergic rhinitis (seasonal and perennial forms) and urticaria (hives).

“Talert supports patients during episodes of heightened discomfort, helping to maintain functional stability when symptoms interfere with routine activities.”


Symptom Management and Clinical Scenarios

Talert assists with maintaining functional stability during periods where symptoms become more noticeable. It is applied during phases of increased distress or discomfort, often used when symptoms intensify and supportive relief is needed for conditions like hay fever or chronic hives. It helps address symptom clusters that may become intense or disruptive, such as sneezing, runny nose, itchy eyes, and intense skin itching. The medication helps patients cope more steadily with symptom fluctuations.


Quick Fact: Relief for Skin and Nasal Itching

Regulatory References

  1. Cetirizine - StatPearls - NIH Guidance

Eligibility and Restrictions for Use

Who Can and Cannot Use Talert?

This section defines population eligibility for Talert (Cetirizine Hydrochloride) strictly according to official governmental regulatory documentation.

Contraindicated Populations

Use of Talert is contraindicated (absolutely prohibited) for patients with a known history of hypersensitivity or allergic reaction to its active substance, Cetirizine Hydrochloride, or any of its inactive ingredients. Contraindication also extends to individuals with hypersensitivity to hydroxyzine, a chemically related compound.

Age-Related and Conditional Eligibility

Eligibility is defined by specific age groups and health status, often requiring professional consultation:

  • Standard Approved Use: Talert is approved for standard use in adults and children 6 years and over.
  • Pediatric Restriction: Use in children under 6 years of age requires consultation with a physician, as does use by adults 65 years and over.
  • Organ Impairment: Patients with moderate or severe renal impairment or hepatic impairment have restricted eligibility and must seek professional guidance, as drug clearance may be reduced.

Physiological Restrictions

Official labeling addresses use during physiological states:

  • Pregnancy: Use during pregnancy requires prior consultation with a health professional.
  • Lactation: Use is not recommended while breastfeeding, as the active substance has been reported to be present in human breast milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes interactions documented in official government regulatory sources, classified by mechanism and restriction.

Pharmacokinetic and Pharmacodynamic Interactions

The co-administration of Talert (Cetirizine Hydrochloride) with Theophylline (at a dosage of 400 mg once daily) resulted in a pharmacokinetic interaction that caused a 16% decrease in the clearance of cetirizine. Separately, the medication is documented as a P-glycoprotein substrate in regulatory information. No clinically significant pharmacokinetic interactions were found in studies with azithromycin, erythromycin, or ketoconazole.

A pharmacodynamic interaction exists with alcohol and other Central Nervous System (CNS) depressants. Concurrent use with these substances may lead to an additive reduction in alertness and increased impairment of performance.

Interaction-Related Restrictions

Substance/Condition Regulatory Constraint
Alcohol / CNS Depressants Concurrent use may cause additional impairment of CNS performance.
Allergy Skin Tests Antihistamines inhibit test response; discontinuation of Talert several days prior to testing is required.
Food Decreases the rate of absorption (Tmax is delayed), but the total amount of drug absorbed is unchanged.

Clearance is officially noted to be reduced in geriatric patients and in those with hepatic or renal impairment, which is a population-specific consideration that may affect the overall impact of co-administered medicines.

Mechanism of Action

How Talert Works

Talert's mechanism is highly specific, operating through the targeted manipulation of regulatory proteins. The drug functions as a molecular glue modulator, binding to the Cereblon ( CRBN) component of the E3 ubiquitin ligase complex. This binding induces the CRBN complex to recognize and tag specific growth-promoting transcription factors (Ikaros and Aiolos) with ubiquitin, marking them for destruction by the cell’s proteasome.

This depletion of transcription factors leads to two primary consequences. First, it results in the inhibition of gene expression for key pro-inflammatory mediators, such as tumor necrosis factor-alpha ( TNF-alpha), thereby modulating the function of immune cells. Second, it interferes with pathways involved in angiogenesis (new blood vessel formation) by modulating factors like VEGF and FGF signaling, resulting in a restricted cellular environment.

Dosage and Administration Information

Talert (Cetirizine Hydrochloride) is administered exclusively by the oral route using approved dosage forms: tablets, oral solution, or syrup. The standard use pattern is a once-daily schedule, allowing for continuous, sustained management of symptoms. The medicine may be ingested with or without food, providing flexibility in the timing of administration.

The maximum dose for adults and adolescents (ge 12 years) is fixed at 10 mg per 24 hours, with typical regimens utilizing 5 mg or 10 mg. The final administered dose is determined by the patient's age and specific physiological status.

Population Group Standard Daily Regimen (Oral) Maximum Daily Dose
Adults & Adolescents (ge 12 years) 5 mg to 10 mg once daily 10 mg
Children (6 to 11 years) 5 mg or 10 mg once daily 10 mg
Children (2 to 5 years) 2.5 mg once daily, up to 5 mg total 5 mg

Dose reduction is required for patients with impaired renal function due to the drug’s elimination characteristics; for example, adult patients with moderate renal impairment often receive 5 mg once daily. The duration of use is contingent upon the clinical need, ranging from short-term acute use to longer-term use for chronic conditions. If a dose is missed, common practice involves skipping it if it is close to the next scheduled time, and not taking a double dose to compensate.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Clinical Trials on [Drug X] Monotherapy

Research has explored whether [Drug X] monotherapy was evaluated for its use in managing acute symptoms. A key Phase 3 clinical trial focusing on 500 adult participants investigated whether [Drug X] alone was associated with changes in symptom relief compared to a placebo.

  • The primary outcome measure assessed changes in a validated pain scale over 24 hours. The findings were heterogeneous, with some subgroups showing differing degrees of change than others.
  • The trials reported on the frequency of side effects and adverse events, noting the most common were generally described as mild and temporary.
  • An extension study tracked participants for 12 weeks and explored changes in symptoms over this longer period.

Studies on the [Drug X] and [Drug Y] Combination

Multiple studies have investigated whether the combination of [Drug X] and [Drug Y] is associated with improved outcomes in managing severe, recurrent conditions. The rationale for this combination centers on the different biological pathways that both compounds address.

  • A randomized controlled trial (RCT) with 350 patients with chronic severe symptoms investigated outcomes related to symptom reduction and relapse rates over six months.
  • Research examined whether this combination was associated with a change in the need for rescue medication in the first month of treatment. Certain studies noted changes in time to onset of symptom relief compared to [Drug X] alone.

Safety and Dosing Regimens

Safety data is available from all major clinical trials. The trials reported on the frequency of side effects and adverse events. Specific focus was placed on cardiovascular events and hepatic function.

  • The reviewed studies utilized a dosing schedule of [Drug X] 50mg, taken once daily.
  • Research did not evaluate the concurrent use of [Drug X] with specific classes of strong metabolic inhibitors, and limited safety data is available for use in pediatric populations.

Frequently Asked Questions (FAQ)

Common questions about Talert (FAQ)


Q: How long does the effect of one Talert dose typically last?

A: The effect of a single dose of Talert is generally described in official information as lasting for at least 24 hours. This duration is consistent with the drug’s labeling as a once-daily medicine.


Q: What is the time frame for Talert to start working?

A: According to official product information, the effects of the medicine typically begin to manifest within 20 to 60 minutes after taking a dose. This time frame is related to how quickly the active substance is absorbed by the body.


Q: Are there any common foods or drinks that interact with Talert?

A: Regulatory documents state that food can influence the rate at which Talert is absorbed. Specifically, food may delay the time it takes for the drug to reach its peak concentration in the blood, but the total amount of drug absorbed by the body is not significantly altered.


Q: Is Talert known to interact with herbal supplements?

A: While specific herbal products are not always listed individually, official regulatory sources advise that patients should inform their health professional about any supplements, herbs, or vitamins being used. This is to help identify potential interactions.


Q: What happens if a person takes more Talert than described in the directions?

A: In reported cases where accidental overdose occurred, the most commonly observed effect was sedation (drowsiness) and feeling sleepy. Official safety information indicates that treatment for overdose is generally described as supportive.


Q: Is Talert associated with high blood pressure?

A: High blood pressure is not commonly listed as an adverse reaction in the official prescribing information for Talert. However, tachycardia (a fast heart rate) is documented as a rare adverse reaction.


Q: What types of tests are needed before starting Talert?

A: Consultation is needed for patients with liver or kidney impairment, as drug clearance may be reduced in these instances. Regulatory documents indicate that dose reduction or close medical guidance may be required.


Q: Is Talert the same type of medicine as [similar drug name]?

A: Talert is classified as a second-generation H1-receptor antagonist. This classification confirms it works to target receptors responsible for allergic reactions. It is chemically related to the older, first-generation antihistamine hydroxyzine.


Q: Can Talert cause weight changes?

A: Weight changes are not listed as a common or frequent adverse reaction in humans in the official product information. Non-clinical studies, specifically those involving animals and high doses, have noted some effects on weight gain.


Q: Does Talert affect sleep or energy levels?

A: Yes, regulatory documents list somnolence (drowsiness) and fatigue among the most common adverse reactions associated with the use of the medicine. These are adverse reactions that affect the nervous system.


Q: Are there any serious side effects associated with Talert that I should know about?

A: Official safety documents list rare adverse reactions that can be significant, including events affecting the immune, cardiac, and hepatobiliary systems. Examples of these significant but rare events include convulsions, tachycardia, and hypersensitivity reactions.


Q: What does the research say about Talert’s effectiveness for its main use?

A: Clinical information indicates the drug is described as helping to relieve symptoms associated with conditions such as allergic rhinitis (hay fever) and chronic idiopathic urticaria (hives).


Q: Have there been long-term studies published on the effects of Talert?

A: Safety data is collected from clinical trials of various durations. Regulatory communications reference experience from patients who have used the drug daily for periods ranging from a few months to years.


Q: If I stop taking Talert suddenly, are there any known general effects?

A: Regulatory warnings describe reports of a rare but severe generalized itching (pruritus) upon discontinuation of the medicine. This is particularly noted following long-term daily use.


Q: Why do doctors check liver function before prescribing Talert?

A: Official labeling indicates that dose reduction may be required for patients with hepatic (liver) impairment. This is because the clearance of the drug from the body may be slowed, potentially increasing its effects.


Q: Can taking Talert cause general changes in mood or personality?

A: Agitation is listed in official adverse reaction reports as an uncommon effect. Other nervous system-related effects like somnolence may also be observed.


Q: What is the approximate time until Talert reaches its maximum effect in the body?

A: The medicine reaches its maximum concentration in the plasma, which is known as the peak concentration, after approximately one hour.


Q: Is there a link between Talert and vision changes?

A: Vision changes are not commonly listed as an adverse reaction for the oral formulation of Talert. However, reduced visual acuity has been noted in clinical trials for the ophthalmic (eye drop) formulation.


Q: What should be avoided while using Talert, according to official sources?

A: Official regulatory information advises avoiding the concurrent use of Talert with alcohol and other Central Nervous System (CNS) depressants. Additionally, official regulatory documentation indicates that discontinuation of the medicine several days before allergy skin testing may be necessary.


Q: Does Talert affect blood sugar levels?

A: Limited non-clinical research has examined the effect of the active substance on blood glucose levels. Some studies have noted changes in post-prandial (after eating) blood sugar.


Q: Are there any specific warnings for people with heart conditions using Talert?

A: Tachycardia (a fast heart rate) is documented as a rare adverse reaction. Clinical trials, however, observed no clinically significant mean increases in QTc, a cardiac function measure.

How should Talert be stored and disposed of?

Talert must be stored and disposed of according to official regulatory documentation to maintain its quality and prevent harm.

Storage Requirements

Storage Scope Official Requirement
Temperature Store at controlled room temperature, 20 C to 25 C (68 F to 77 F). Do not freeze.
Protection Keep the container tightly closed; the oral solution/syrup must be stored away from light.
Stability Do not use the product after the expiry date. The oral solution/syrup must be used within 6 months of the bottle being opened.
Child Safety Keep the medicine out of the sight and reach of children.

Disposal Instructions

Unused or expired Talert must be handled according to local regulations, with drug take-back programs being the preferred method. Regulatory guidelines advise against disposal into wastewater (sewers or surface water). If disposal via household trash is necessary, the medicine must first be mixed with an undesirable substance, placed in a sealed container, and all identifying information must be removed from the packaging.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Talert found in:

A-Z Index: